[6-K] PainReform Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.

The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.

Positive

• Completed strategic investment in LayerBio to enter the global cataract surgery market.
• Targets a $9 billion global cataract surgery opportunity with a non-opiate, non-steroidal postoperative NSAID drug delivery system.
• The press release is filed as Exhibit 99.1 and its first paragraph is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.

Negative

• None.

Insights

Biotech Industry Specialist

TL;DR: Completed investment positions PainReform to access a $9B cataract surgery market via LayerBio’s postoperative NSAID delivery technology.

The filing announces a strategic investment that explicitly targets the global cataract surgery market and highlights a non-opiate, non-steroidal postoperative NSAID drug delivery system. For industry stakeholders, the material fact is the company’s entry strategy into a sizeable surgical market through an equity/strategic stake rather than an immediate product launch. The disclosure is potentially positive because it signals a directional shift into surgical drug delivery and a partnership/investment route to commercialization, but the filing lacks transaction economics, clinical status, or timelines needed to assess near-term commercial impact.

Corporate Governance and Capital Markets Analyst

TL;DR: The Form 6-K documents a material strategic investment and incorporates a press release by reference but provides limited transactional detail.

From a disclosure and market perspective, the company has met public reporting requirements by furnishing the press release as Exhibit 99.1 and incorporating its opening paragraph into registration statements. The filing is informative about strategic direction but neutral in valuation terms because it does not include deal size, equity stake, accounting treatment, or expected timing. Investors seeking financial impact must await additional disclosures with quantitative detail.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-39481

PainReform Ltd.

(Translation of registrant’s name into English)

65 Yigal Alon St., Tel Aviv 6744316

Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This first paragraph of the press release attached as Exhibit 99.1 to this Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485, 333-277594, 333-283655 and 333-286941), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

On August 13, 2025, PainReform Ltd. issued a press release entitled “PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated August 13, 2025.

 SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 13, 2025	PAINREFORM LTD.
	By:	/s/ Ehud Geller
		Ehud Geller Executive Chairman of the Board and Interim Chief Executive Officer

FAQ

What did PainReform (PRFX) report in this Form 6-K?

The company reported it completed a strategic investment in LayerBio to enter the global cataract surgery market and attached the related press release as Exhibit 99.1.

When was the press release attached to the Form 6-K issued?

The press release attached as Exhibit 99.1 is dated August 13, 2025.

Does the filing disclose the financial terms or size of the investment?

No. The Form 6-K text provided does not include any financial terms, transaction size, or equity stake details.

Does the filing include clinical or commercial results for the LayerBio technology?

No. The Form 6-K does not provide clinical data, regulatory approvals, or commercial performance information.

How does this filing affect the company’s registration statements?

The filing states the first paragraph of the attached press release is incorporated by reference into PainReform’s Form S-8 and Form F-3 registration statements.

What market opportunity is referenced in the press release?

The press release describes the target opportunity as the $9 billion global cataract surgery market and references a postoperative NSAID drug delivery system that is non-opiate and non-steroidal.